The impact of lipid-lowering medications on coronary artery plaque characteristics
Atherosclerosis is the predominant cause of coronary artery disease. The last several decades have witnessed significant advances in lipid-lowering therapies, which comprise a central component of atherosclerotic cardiovascular disease prevention. In addition to cardiovascular risk reduction with dy...
Saved in:
Main Authors: | Vishnu Priya Pulipati (Author), Francis J. Alenghat (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Atherosclerotic coronary plaque regression from lipid-lowering therapies: A meta-analysis and meta-regression
by: Frederick Berro Rivera, et al.
Published: (2024) -
PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease
by: Natalia Pauli, et al.
Published: (2020) -
The association of sex-specific hormones with coronary artery plaque characteristics from Miami Heart (MiHeart) study
by: Yaa A. Kwapong, et al.
Published: (2023) -
Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease-A Narrative Clinical Review
by: Nikolaos Velidakis, et al.
Published: (2024) -
Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment
by: Lluís Masana, et al.
Published: (2023)